Q2 2025 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2025-08-14 · accession 0001892134-25-000006
$2.50B
Reported value
49
Positions
2025-06-30
Period end
The Brief · Frazier Life Sciences Management, L.P. · Q2 2025
AI · grounded in 13F
Frazier Life Sciences Management, L.P. established a new position in MIRM valued at $345.8M. The fund also initiated new stakes in VRNA for $320.1M and NAMS for $300.8M. Additional new positions include BBIO at $164.1M and ARQT at $138.4M. Total assets under management stand at $2.5B across 49 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $345.8M | 13.8% | 6,795,121 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $320.1M | 12.8% | 3,383,950 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $300.8M | 12.0% | 16,607,074 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $164.1M | 6.56% | 3,800,457 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $138.4M | 5.54% | 9,874,511 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $119.6M | 4.78% | 12,466,489 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $94.6M | 3.78% | 688,460 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $87.6M | 3.50% | 1,654,834 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $68.3M | 2.73% | 5,985,347 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $56.6M | 2.26% | 1,397,527 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $56.1M | 2.24% | 10,259,409 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $56.0M | 2.24% | 4,567,275 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $55.3M | 2.21% | 4,887,867 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $45.7M | 1.83% | 1,308,138 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $42.6M | 1.70% | 1,279,754 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $36.7M | 1.47% | 997,455 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $35.8M | 1.43% | 983,715 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $31.9M | 1.28% | 5,100,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $28.9M | 1.15% | 22,729,436 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $28.6M | 1.14% | 1,000,647 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $26.1M | 1.05% | 11,462,301 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $25.6M | 1.02% | 9,440,112 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $23.0M | 0.92% | 133,333 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $22.4M | 0.90% | 2,435,550 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $21.1M | 0.84% | 10,617,062 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $20.0M | 0.80% | 770,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $19.6M | 0.78% | 366,784 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $18.3M | 0.73% | 554,731 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $17.8M | 0.71% | 4,424,725 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $17.8M | 0.71% | 625,000 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $17.7M | 0.71% | 1,772,116 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $16.3M | 0.65% | 722,400 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $15.4M | 0.62% | 474,405 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $14.8M | 0.59% | 1,002,092 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $14.3M | 0.57% | 1,505,984 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $12.5M | 0.50% | 1,734,601 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $12.1M | 0.48% | 384,782 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $10.8M | 0.43% | 1,065,334 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $10.5M | 0.42% | 4,623,324 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $8.2M | 0.33% | 1,458,333 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $7.3M | 0.29% | 453,685 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $6.6M | 0.26% | 1,953,547 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $6.5M | 0.26% | 583,327 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $5.6M | 0.23% | 970,130 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $4.4M | 0.17% | 3,868,750 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $4.0M | 0.16% | 500,333 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $3.8M | 0.15% | 3,175,665 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $2.3M | 0.09% | 1,069,244 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $2.2M | 0.09% | 5,993,579 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.